Literature DB >> 18035073

Matrix metalloproteinase circulating levels, genetic polymorphisms, and susceptibility to acute myocardial infarction among patients with coronary artery disease.

Mark A Hlatky1, Euan Ashley, Thomas Quertermous, Derek B Boothroyd, Paul Ridker, Audrey Southwick, Richard M Myers, Carlos Iribarren, Stephen P Fortmann, Alan S Go.   

Abstract

OBJECTIVE: The aim of this study was to assess systematic differences between patients with acute myocardial infarction (MI) and patients with stable angina in matrix metalloproteinase (MMP) circulating levels and genetic polymorphisms.
METHODS: We identified adults in a large integrated health care delivery system whose initial clinical presentation of coronary disease was either an acute MI or stable exertional angina. A total of 909 patients with acute MI, 466 patients with stable angina, and 1023 healthy older control subjects were genotyped. Serum levels of pro-MMP1, MMP2, MMP3, MMP9, and MMP10 were measured in 199 randomly selected patients from each group.
RESULTS: At a median of 15 weeks after initial clinical presentation, higher circulating levels of MMP2 and MMP9 were independently associated with acute MI after statistical adjustment for conventional risk factors, hs-CRP levels, and cardiac medications. By contrast, none of the polymorphisms in MMP1, MMP2, MMP3, MMP9, or MMP10 was significantly associated with either acute MI compared with angina, or with coronary disease compared with controls.
CONCLUSIONS: Circulating levels of MMP2 and MMP9 are independently associated with development of an acute MI rather than stable angina as the initial clinical presentation of coronary artery disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18035073     DOI: 10.1016/j.ahj.2007.06.042

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  29 in total

1.  Circulating markers of vascular injury and angiogenesis in antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Paul A Monach; Gunnar Tomasson; Ulrich Specks; John H Stone; David Cuthbertson; Jeffrey Krischer; Linna Ding; Fernando C Fervenza; Barri J Fessler; Gary S Hoffman; David Ikle; Cees G M Kallenberg; Carol A Langford; Mark Mueller; Philip Seo; E William St Clair; Robert Spiera; Nadia Tchao; Steven R Ytterberg; Yi-Zhong Gu; Ronald D Snyder; Peter A Merkel
Journal:  Arthritis Rheum       Date:  2011-12

2.  Matrix metalloproteinase therapy in heart failure.

Authors:  Francis G Spinale; Nikole M Wilbur
Journal:  Curr Treat Options Cardiovasc Med       Date:  2009-08

3.  Association of matrix metalloproteinase-2 gene promoter polymorphism with myocardial infarction susceptibility in a Mexican population.

Authors:  Ivan Delgado-Enciso; Nelida A Gonzalez-Hernandez; Luz M Baltazar-Rodriguez; Rebeca O Millan-Guerrero; Oscar Newton-Sanchez; Alfonso Bayardo-Noriega; Alfonso Aleman-Mireles; Irma G Enriquez-Maldonado; Ma J Anaya-Carrillo; Augusto Rojas-Martinez; Rocio Ortiz-Lopez
Journal:  J Genet       Date:  2009-08       Impact factor: 1.166

Review 4.  Intramyocardial haemorrhage after acute myocardial infarction.

Authors:  Ryanne P Betgem; Guus A de Waard; Robin Nijveldt; Aernout M Beek; Javier Escaned; Niels van Royen
Journal:  Nat Rev Cardiol       Date:  2014-11-18       Impact factor: 32.419

Review 5.  Changes in the myocardial interstitium and contribution to the progression of heart failure.

Authors:  Shaina R Eckhouse; Francis G Spinale
Journal:  Heart Fail Clin       Date:  2012-01       Impact factor: 3.179

6.  A comparison of vascular effects from complex and individual air pollutants indicates a role for monoxide gases and volatile hydrocarbons.

Authors:  Matthew J Campen; Amie K Lund; Melanie L Doyle-Eisele; Jacob D McDonald; Travis L Knuckles; Annette C Rohr; Eladio M Knipping; Joe L Mauderly
Journal:  Environ Health Perspect       Date:  2010-03-02       Impact factor: 9.031

7.  Peroxisome proliferator-activated receptor gamma polymorphisms and coronary heart disease.

Authors:  Jean Dallongeville; Carlos Iribarren; Jean Ferrières; Liisa Lyon; Alun Evans; Alan S Go; Dominique Arveiler; Stephen P Fortmann; Pierre Ducimetière; Mark A Hlatky; Philippe Amouyel; Audrey Southwick; Thomas Quertermous; Aline Meirhaeghe
Journal:  PPAR Res       Date:  2009-12-01       Impact factor: 4.964

8.  NT-proBNP and circulating inflammation markers in prediction of a normal myocardial scintigraphy in patients with symptoms of coronary artery disease.

Authors:  Camilla Noelle Rathcke; Erik Kjøller; Niels Fogh-Andersen; Bo Zerahn; Henrik Vestergaard
Journal:  PLoS One       Date:  2010-12-01       Impact factor: 3.240

Review 9.  Translating Koch's postulates to identify matrix metalloproteinase roles in postmyocardial infarction remodeling: cardiac metalloproteinase actions (CarMA) postulates.

Authors:  Rugmani Padmanabhan Iyer; Lisandra E de Castro Brás; Yu-Fang Jin; Merry L Lindsey
Journal:  Circ Res       Date:  2014-02-28       Impact factor: 17.367

10.  Prospective study of matrix metalloproteinase-9 and risk of myocardial infarction and stroke in older men and women.

Authors:  Barbara J Jefferis; Peter Whincup; Paul Welsh; Goya Wannamethee; Ann Rumley; Lucy Lennon; Andy Thomson; Debbie Lawlor; Claire Carson; Shah Ebrahim; Gordon Lowe
Journal:  Atherosclerosis       Date:  2009-08-19       Impact factor: 5.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.